Tema Etfs LLC Sells 4,416 Shares of Insmed, Inc. $INSM

Tema Etfs LLC reduced its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 48.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,765 shares of the biopharmaceutical company’s stock after selling 4,416 shares during the quarter. Tema Etfs LLC’s holdings in Insmed were worth $480,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of INSM. Vanguard Group Inc. boosted its holdings in shares of Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock worth $1,393,675,000 after acquiring an additional 49,149 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Insmed by 1.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock valued at $985,938,000 after buying an additional 219,131 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Insmed by 109.2% during the first quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock valued at $262,967,000 after buying an additional 1,799,382 shares during the period. Artisan Partners Limited Partnership lifted its holdings in shares of Insmed by 3.0% in the second quarter. Artisan Partners Limited Partnership now owns 3,314,341 shares of the biopharmaceutical company’s stock worth $333,555,000 after buying an additional 97,073 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of Insmed by 2.5% in the first quarter. Alliancebernstein L.P. now owns 2,423,513 shares of the biopharmaceutical company’s stock valued at $184,890,000 after acquiring an additional 59,952 shares during the period.

Analyst Ratings Changes

Several brokerages have commented on INSM. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a report on Wednesday, October 8th. JPMorgan Chase & Co. lifted their price objective on Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, August 20th. Morgan Stanley upped their target price on Insmed from $126.00 to $144.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 21st. Mizuho lifted their price target on Insmed from $196.00 to $256.00 and gave the company an “outperform” rating in a research report on Monday. Finally, Wells Fargo & Company upped their price objective on shares of Insmed from $171.00 to $217.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $187.89.

Insider Buying and Selling

In related news, insider Michael Alexander Smith sold 27,130 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the transaction, the insider directly owned 54,902 shares in the company, valued at $10,089,889.56. This trade represents a 33.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elizabeth M. Anderson sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $195.87, for a total value of $1,958,700.00. Following the completion of the sale, the director owned 63,729 shares of the company’s stock, valued at $12,482,599.23. The trade was a 13.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 233,650 shares of company stock worth $41,063,785 over the last 90 days. Insiders own 3.00% of the company’s stock.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $204.00 on Friday. The stock’s 50-day moving average is $180.50 and its 200 day moving average is $134.48. The stock has a market cap of $43.51 billion, a price-to-earnings ratio of -32.96 and a beta of 1.01. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The business had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The firm’s revenue was up 52.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.27) earnings per share. On average, sell-side analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.